A Phase 2 interventional study of dimethyl fumarate in Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis, sponsored by Biogen. Completed at 16 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-03-21.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 10th largest by enrollment, is the only one that started in 2010, is one of 2 in phase 2, and was the 5th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2010.
This study's enrollment of 108 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 34th largest by enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2010, is one of 9 in phase 2, and was the 30th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
Drug: dimethyl fumarate
Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
Drug: dimethyl fumarate
Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
Also known as: Tecfidera, DMF, BG00012
Summary of Treatment-emergent Adverse Events (TEAEs) Occurring Post-BG00012 Dosing (Add-on Therapy Period)
An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; was any other medically important event that, in the opinion of the Investigator, jeopardized the participant or required intervention to prevent one of the other outcomes above. TEAE was defined as having an onset date that was on or after the start of study treatment (BG00012), or that worsened after the start of study treatment.
Time frame: AEs were collected from enrollment until the final study visit (Week 26 +/-5 days).
Potentially Clinically Significant Hematology Laboratory Abnormalities for Combination Therapy
Percentage of participants with potentially clinically significant hematology laboratory abnormalities.
Time frame: collected from the start of BG00012 administration through to Week 26 +/- 5 days
Maximum Post-Baseline Values: Liver Enzymes for Combination Therapy
Percentage of participants with post-baseline liver enzyme values above the upper limit of normal (ULN). Liver enzymes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and bilirubin. Elevated ALT/AST (ALT/AST ≥ 3\*ULN) concurrent with elevated total bilirubin was also evaluated.
Time frame: collected from the start of BG00012 administration through to Week 26 +/- 5 days
Worst Post-Baseline Values for Selected Urinalysis Parameters That Require Further Evaluation for Combination Therapy
Percentage of participants with post-baseline values for selected urinalysis parameters requiring further evaluation. For urine microscopy, results were categorized for male and female participants. For males, normal/negative was considered 0 to 3 red blood cells/high-power field (rbc/hpf), and positive was categorized in the following stages: 4 to 10, 11 to 20, 21 to 149, and ≥ 150 rbc/hpf. For females, normal/negative was considered 0 to 8 rbc/hpf, and positive was categorized in the following stages: 9 to 20, 21 to 30, 31 to 149, and ≥ 150 rbc/hpf.
Time frame: collected from the start of BG00012 administration through to Week 26 +/- 5 days
Summary of Adverse Events (AEs) Occurring Before BG00012 Dosing (Monotherapy Period)
Percentage of participants with AEs, serious AEs (SAEs), and discontinuations due to AEs. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug. An SAE was any untoward medical occurrence that, at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; was any other medically important event that, in the opinion of the Investigator, jeopardized the participant or required intervention to prevent one of the other outcomes above. AEs were categorized as mild, moderate, or severe. All AEs occurring from enrollment to the day before BG00012 dosing are included.
Time frame: from time of enrollment until day before first administration of BG00012 (Week -8 to Week 0)
Average Number of Gadolinium (Gd)-Enhancing Lesions: Week -8, -4, 0 Average Versus Week 16, 20, 24 Average
The average is calculated as (total number of lesions in non-missing scans / number of non-missing magnetic resonance imaging \[MRI\] scans).
Time frame: Week -8 through Week 24
Average Number of New Gd-Enhancing Lesions: Weeks -4, 0 Average Versus Weeks 20, 24 Average
The average is calculated as (total number of lesions in non-missing scans / number of non-missing MRI scans).
Time frame: Week -4 through Week 24
Number of New or Newly Enlarging T2 Lesions
The number of new T2 lesions divided by the number of months since the reference visit during the Monotherapy Period and the Add-On Therapy Period.
Time frame: Week -8 to Week 24
| Milestone | Monotherapy Period: Interferon Beta (IFNß) | Monotherapy Period: Glatiramer Acetate (GA) | Add-on Therapy Period: Dimethyl Fumarate Add-on to IFNß | Add-on Therapy Period: Dimethyl Fumarate Add-on to GA |
|---|---|---|---|---|
| Started | 59 | 49 | 0 | 0 |
| Completed | 57 | 47 | 0 | 0 |
| Not completed | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Milestone | Monotherapy Period: Interferon Beta (IFNß) | Monotherapy Period: Glatiramer Acetate (GA) | Add-on Therapy Period: Dimethyl Fumarate Add-on to IFNß | Add-on Therapy Period: Dimethyl Fumarate Add-on to GA |
|---|---|---|---|---|
| Started | 0 | 0 | 57 | 47 |
| Completed bg00012 combination therapy | 0 | 0 | 45 | 38 |
| Completed | 0 | 0 | 45 | 37 |
| Not completed | 0 | 0 | 12 | 10 |
| Withdrew: Adverse event | 0 | 0 | 7 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 |
| Withdrew: Disease activity | 0 | 0 | 1 | 2 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 2 |
Percentage of participants with AEs, serious AEs (SAEs), and discontinuations due to AEs. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug. An SAE was any untoward medical occurrence that, at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; was any other medically important event that, in the opinion of the Investigator, jeopardized the participant or required intervention to prevent one of the other outcomes above. AEs were categorized as mild, moderate, or severe. All AEs occurring from enrollment to the day before BG00012 dosing are included.
| percentage of participants | Monotherapy Period: IFNß | Monotherapy Period: GA |
|---|---|---|
| Participants with an AE | 56 | 49 |
| Participants with a moderate or severe AE | 22 | 27 |
| Participants with a severe AE | 3 | 0 |
| Participants with an SAE | 0 | 0 |
| Participants withdrawing from study due to an AE | 0 | 0 |
An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; was any other medically important event that, in the opinion of the Investigator, jeopardized the participant or required intervention to prevent one of the other outcomes above. TEAE was defined as having an onset date that was on or after the start of study treatment (BG00012), or that worsened after the start of study treatment.
| percentage of participants | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| Participants with a TEAE | 95 | 100 |
| Participants with a moderate or severe TEAE | 72 | 70 |
| Participants with a severe TEAE | 14 | 15 |
| Participants with a related TEAE | 74 | 87 |
| Participants with a serious TEAE | 4 | 2 |
| Participants discontinuing BG00012 due to a TEAE | 14 | 17 |
| Participants withdrawing from study due to a TEAE | 14 | 17 |
Percentage of participants with potentially clinically significant hematology laboratory abnormalities.
| percentage of participants | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| White Blood Cells (total) < 3.0*10^9/L | 9 | 2 |
| White Blood Cells (total) ≥ 16*10^9/L | 2 | 2 |
| Lymphocytes < 0.8*10^9/L | 32 | 6 |
| Lymphocytes < 0.5*10^9/L | 7 | 4 |
| Lymphocytes > 12*10^9/L | 0 | 0 |
| Neutrophils ≤ 1.0*10^9/L | 0 | 0 |
| Neutrophils < 1.5*10^9/L | 13 | 2 |
| Neutrophils ≥ 12*10^9/L | 2 | 4 |
| Red Blood Cells ≤ 3.3*10^12/L | 0 | 0 |
| Red Blood Cells ≥ 6.8*10^12/L | 0 | 0 |
| Hemoglobin g/L ≤ 100 | 0 | 0 |
| Platelet Count ≤ 100*10^9/L | 0 | 0 |
| Platelet Count ≥ 600*10^9/L | 0 | 0 |
Percentage of participants with post-baseline liver enzyme values above the upper limit of normal (ULN). Liver enzymes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and bilirubin. Elevated ALT/AST (ALT/AST ≥ 3\*ULN) concurrent with elevated total bilirubin was also evaluated.
| percentage of participants | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| ALT ≤ 1*ULN | 47 | 47 |
| ALT > 1*ULN | 53 | 53 |
| ALT ≥ 3*ULN | 5 | 2 |
| ALT > 5*ULN | 2 | 0 |
| ALT > 10*ULN | 0 | 0 |
| ALT > 20*ULN | 0 | 0 |
| AST ≤ 1*ULN | 68 | 64 |
| AST > 1*ULN | 32 | 36 |
| AST ≥ 3*ULN | 2 | 0 |
| AST > 5*ULN | 0 | 0 |
| AST > 10*ULN | 0 | 0 |
| AST > 20*ULN | 0 | 0 |
| GGT ≤ 1*ULN | 72 | 85 |
| GGT > 1*ULN | 28 | 15 |
| GGT ≥ 3*ULN | 4 | 0 |
| GGT > 5*ULN | 2 | 0 |
| GGT > 10*ULN | 0 | 0 |
| GGT > 20*ULN | 0 | 0 |
| Total Bilirubin ≤ 1*ULN | 98 | 94 |
| Total Bilirubin > 1*ULN | 2 | 6 |
| Total Bilirubin > 1.5*ULN | 0 | 4 |
| Total Bilirubin > 2*ULN | 0 | 2 |
| ALT/AST ≥ 3*ULN + Total Bilirubin > 1.5*ULN | 0 | 0 |
| ALT/AST ≥ 3*ULN + Total Bilirubin > 2*ULN | 0 | 0 |
Percentage of participants with post-baseline values for selected urinalysis parameters requiring further evaluation. For urine microscopy, results were categorized for male and female participants. For males, normal/negative was considered 0 to 3 red blood cells/high-power field (rbc/hpf), and positive was categorized in the following stages: 4 to 10, 11 to 20, 21 to 149, and ≥ 150 rbc/hpf. For females, normal/negative was considered 0 to 8 rbc/hpf, and positive was categorized in the following stages: 9 to 20, 21 to 30, 31 to 149, and ≥ 150 rbc/hpf.
| percentage of participants | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| Urine blood: normal/negative; n=57, 47 | 75 | 64 |
| Urine blood: trace; n=57, 47 | 7 | 9 |
| Urine blood: 1+; n=57, 47 | 5 | 15 |
| Urine blood: 2+; n=57, 47 | 7 | 11 |
| Urine blood: 3+; n=57, 47 | 5 | 2 |
| Urine protein: normal/negative; n=57, 47 | 39 | 38 |
| Urine protein: trace; n=57, 47 | 35 | 45 |
| Urine protein: 1+; n=57, 47 | 26 | 15 |
| Urine protein: 2+; n=57, 47 | 0 | 2 |
| Urine protein: 3+; n=57, 47 | 0 | 0 |
| Urine protein: 4+; n=57, 47 | 0 | 0 |
| Urine glucose: normal/negative; n=57, 47 | 93 | 94 |
| Urine glucose: trace; n=57, 47 | 2 | 0 |
| Urine glucose: 1+; n=57, 47 | 2 | 2 |
| Urine glucose: 2+; n=57, 47 | 0 | 4 |
| Urine glucose: 3+; n=57, 47 | 2 | 0 |
| Urine glucose: 4+; n=57, 47 | 2 | 0 |
| Urine ketone: normal/negative; n=57, 47 | 47 | 57 |
| Urine ketone: trace; n=57, 47 | 9 | 11 |
| Urine ketone: 1+; n=57, 47 | 26 | 28 |
| Urine ketone: 2+; n=57, 47 | 11 | 4 |
| Urine ketone: 3+; n=57, 47 | 4 | 0 |
| Urine ketone: 4+; n=57, 47 | 4 | 0 |
| Urine microscopy (male): 0-3 rbc/hpf; n=9, 16 | 100 | 75 |
| Urine microscopy (male): 4-10 rbc/hpf; n=9, 16 | 0 | 6 |
| Urine microscopy (male): 11-20 rbc/hpf; n=9, 16 | 0 | 13 |
| Urine microscopy (male): 21-149 rbc/hpf; n=9, 16 | 0 | 6 |
| Urine microscopy (male): ≥ 150 rbc/hpf; n=9, 16 | 0 | 0 |
| Urine microscopy (female): 0-8 rbc/hpf; n=25, 28 | 76 | 86 |
| Urine microscopy (female): 9-20 rbc/hpf; n=25, 28 | 8 | 4 |
| Urine microscopy (female): 21-30 rbc/hpf; n=25, 28 | 4 | 0 |
| Urine microscopy (female): 31-149 rbc/hpf;n=25, 28 | 0 | 7 |
| Urine microscopy (female): ≥150 rbc/hpf; n=25, 28 | 12 | 4 |
The average is calculated as (total number of lesions in non-missing scans / number of non-missing magnetic resonance imaging \[MRI\] scans).
| lesions | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| Average number of lesions from Weeks -8, -4, 0 | 1.06 ± 1.011 | 1.72 ± 1.098 |
| Average number of lesions from Weeks 16, 20, 24 | 0.17 ± 0.243 | 0.83 ± 2.115 |
| Change from average of Weeks -8, -4, 0 | -0.90 ± 0.902 | -0.89 ± 2.264 |
The average is calculated as (total number of lesions in non-missing scans / number of non-missing MRI scans).
| lesions | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| Average number of lesions from Weeks -4, 0 | 0.91 ± 0.953 | 0.79 ± 0.985 |
| Average number of lesions from Weeks 20, 24 | 0.06 ± 0.171 | 0.18 ± 0.303 |
| Change from average of Weeks -4, 0 | -0.84 ± 0.978 | -0.62 ± 1.054 |
The number of new T2 lesions divided by the number of months since the reference visit during the Monotherapy Period and the Add-On Therapy Period.
| lesions per month | Interferon Beta 1a (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) |
|---|---|---|
| New lesions in the Monotherapy Period | 1.23 ± 1.498 | 0.89 ± 1.243 |
| New lesions in the Add-on Therapy Period | 0.67 ± 1.257 | 0.25 ± 0.293 |
Collected over AEs for the Monotherapy Period collected from enrollment until prior to administration of BG00012. TEAEs for the Add-on Therapy Period collected from start of BG00012 until the final study visit (Week 26 +/-5 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy Period: IFNß | — | 0/59 (0%) | 13/59 (22%) |
| Monotherapy Period: GA | — | 0/49 (0%) | 7/49 (14.3%) |
| Add-on Therapy Period: IFNß and BG00012 | — | 2/57 (3.5%) | 53/57 (93%) |
| Add-on Therapy Period: GA and BG00012 | — | 1/47 (2.1%) | 45/47 (95.7%) |
| Event | Monotherapy Period: IFNß | Monotherapy Period: GA | Add-on Therapy Period: IFNß and BG00012 | Add-on Therapy Period: GA and BG00012 |
|---|---|---|---|---|
| Clostridial infectionInfections and infestations | 0/59 | 0/49 | 0/57 | 1/47 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/59 | 0/49 | 1/57 | 0/47 |
| Abdominal pain upperGastrointestinal disorders | 0/59 | 0/49 | 1/57 | 0/47 |
| Gastrointestinal painGastrointestinal disorders | 0/59 | 0/49 | 1/57 | 0/47 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/59 | 0/49 | 1/57 | 0/47 |
| Event | Monotherapy Period: IFNß | Monotherapy Period: GA | Add-on Therapy Period: IFNß and BG00012 | Add-on Therapy Period: GA and BG00012 |
|---|---|---|---|---|
| FlushingVascular disorders | 0/59 | 0/49 | 24/57 | 25/47 |
| DiarrhoeaGastrointestinal disorders | 0/59 | 0/49 | 18/57 | 7/47 |
| Abdominal PainGastrointestinal disorders | 0/59 | 0/49 | 12/57 | 3/47 |
| NauseaGastrointestinal disorders | 0/59 | 0/49 | 11/57 | 4/47 |
| Multiple Sclerosis RelapseNervous system disorders | 8/59 | 2/49 | 10/57 | 7/47 |
| HeadacheNervous system disorders | 0/59 | 0/49 | 9/57 | 7/47 |
| Urinary Tract InfectionInfections and infestations | 3/59 | 4/49 | 2/57 | 7/47 |
| NasopharyngitisInfections and infestations | 3/59 | 1/49 | 8/57 | 7/47 |
| Alanine Aminotransferase IncreasedInvestigations | 0/59 | 0/49 | 6/57 | 7/47 |
| DizzinessNervous system disorders | 0/59 | 0/49 | 8/57 | 3/47 |
Intent-to-Treat (ITT) Population: participants who took at least 1 capsule of BG00012 concurrently with the background therapy (combination therapy).
| Age, Continuous(years) | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) | Total |
|---|---|---|---|
| Mean | 39.5 ± 7.58 | 40.7 ± 8.44 | 40.1 ± 7.96 |
| Age, Customized(participants) | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) | Total |
|---|---|---|---|
| 18 to 19 years | 1 | 0 | 1 |
| 20 to 29 years | 5 | 3 | 8 |
| 30 to 39 years | 18 | 22 | 40 |
| 40 to 49 years | 27 | 15 | 42 |
| 50 to 55 years | 6 | 7 | 13 |
| Sex: Female, Male(Participants) | Interferon Beta (IFNß) and BG00012 (Dimethyl Fumarate) | Glatiramer Acetate (GA) and BG00012 (Dimethyl Fumarate) | Total |
|---|---|---|---|
| Female | 40 | 29 | 69 |
| Male | 17 | 18 | 35 |
The record gives a start of Jun 2010, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →